Compare FDBC & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FDBC | VYGR |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.7M | 226.8M |
| IPO Year | N/A | 2015 |
| Metric | FDBC | VYGR |
|---|---|---|
| Price | $42.90 | $4.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 10.1K | ★ 375.7K |
| Earning Date | 01-28-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.96% | N/A |
| EPS Growth | ★ 68.46 | N/A |
| EPS | ★ 4.51 | N/A |
| Revenue | ★ $88,597,000.00 | $31,316,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $71.78 |
| P/E Ratio | $9.43 | ★ N/A |
| Revenue Growth | ★ 24.36 | N/A |
| 52 Week Low | $37.00 | $2.65 |
| 52 Week High | $50.00 | $5.96 |
| Indicator | FDBC | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 46.28 |
| Support Level | $41.00 | $3.89 |
| Resistance Level | $43.48 | $4.19 |
| Average True Range (ATR) | 1.13 | 0.19 |
| MACD | -0.38 | 0.00 |
| Stochastic Oscillator | 26.60 | 50.57 |
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers. Company includes segments: Commercial and Industrial, Commercial Real Estate, Consumer, Residential Real Estate.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.